Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity

Journal of Immunology

Volumn 198, Issue 8, 2017, Pages 3023-3028

  Betancourt, Dillon ^a   De Queiroz, Nina M G P ^a   Xia, Tianli ^a   Ahn, Jeonghyun ^a   Barber, Glen N ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN E, FLAVIVIRUS; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PROGENY; PROTEIN EXPRESSION; UPREGULATION; VESICULOVIRUS; VIRUS REPLICATION; VIRUS TITRATION; ZIKA FEVER; ZIKA VIRUS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; IMMUNOBLOTTING; IMMUNOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; ZIKA VIRUS INFECTION;

EID: 85017341081     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1602180     Document Type: Article

References (15)

1. Weaver, S. C., F. Costa, M. A. Garcia-Blanco, A. I. Ko, G. S. Ribeiro, G. Saade, P. Y. Shi, and N. Vasilakis. 2016. Zika virus: history, emergence, biology, and prospects for control. Antiviral Res. 130: 69-80.
2. Focosi, D., F. Maggi, and M. Pistello. 2016. Zika virus: implications for public health. Clin. Infect. Dis. 63: 227-233.
3. Rasmussen, S. A., D. J. Jamieson, M. A. Honein, and L. R. Petersen. 2016. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374: 1981-1987.
4. Musso, D., C. Roche, E. Robin, T. Nhan, A. Teissier, and V. M. Cao-Lormeau. 2015. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21: 359-361.
5. Pierson, T. C., and B. S. Graham. 2016. Zika virus: immunity and vaccine development. Cell 167: 625-631.
6. Waddell, L. A., and J. D. Greig. 2016. Scoping review of the Zika virus literature. PLoS One 11: e0156376.
7. Cutchins, E., J. Warren, and W. P. Jones. 1960. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol. 85: 275-283.
8. Heiber, J. F., and G. N. Barber. 2011. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J. Virol. 85: 10440-10450.
9. Faria, P. A., P. Chakraborty, A. Levay, G. N. Barber, H. J. Ezelle, J. Enninga, C. Arana, J. van Deursen, and B. M. Fontoura. 2005. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 17: 93-102.
10. Konishi, E., and P. W. Mason. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67: 1672-1675.
11. Iyer, A. V., B. Pahar, M. J. Boudreaux, N. Wakamatsu, A. F. Roy, V. N. Chouljenko, A. Baghian, C. Apetrei, P. A. Marx, and K. G. Kousoulas. 2009. Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27: 893-903.
12. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76: 895-904.
13. Wertz, G. W., R. Moudy, and L. A. Ball. 2002. Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J. Virol. 76: 7642-7650.
14. Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50: 135-138.
15. Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77: 8843-8856.